TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38445314

Group type: EXPERIMENTAL
Intervention: Manualized home-based rehabilitation intervention
Number of subjects: 60
Study: 38445317

Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg (Group 2)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard care (Group 1)
Number of subjects: 37
Study: 38445382

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 International Units prior to each session of psychotherapy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 38445434

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 50
Study: 38445445

Group type: EXPERIMENTAL
Intervention: Anlotinib plus the STUPP regimen
Number of subjects: 33
Study: 38445452

Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm using all available variables
Number of subjects: 76457

Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm using only preoperative variables
Number of subjects: 76457

Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm with top 40 features
Number of subjects: 76457

Group type: EXPERIMENTAL
Intervention: Gradient boosting decision trees algorithm with top 10 features
Number of subjects: 76457

Group type: EXPERIMENTAL
Intervention: Machine learning models with only preoperative variables or only important predictors
Number of subjects: 76457
Study: 38445487

Group type: EXPERIMENTAL
Intervention: Compression-only CPR
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 1250
Study: 38445499

Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster α (45 patients, 18.3%)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster β (105 patients, 42.7%)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: PWR trajectory cluster γ (96 patients, 39.0%)
Number of subjects: 246
Study: 38445521

Group type: EXPERIMENTAL
Intervention: SEBE-HCNNSS scale
Number of subjects: 177
Study: 38445541

Group type: EXPERIMENTAL
Intervention: Mitiperstat 5 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 38445651

Group type: EXPERIMENTAL
Intervention: 0.5 mg low-dose melatonin administered 3 hours before the measured DLMO (measured DLMO group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 mg low-dose melatonin administered 5 hours before sleep-onset time per actigraphy (estimated DLMO group, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (evening dim light and time in bed scheduling)
Number of subjects: 40
Study: 38445744

Group type: EXPERIMENTAL
Intervention: 24-hour recall period
Number of subjects: 1692

Group type: COMPARATOR
Intervention: 7-day recall period
Number of subjects: 1692
Study: 38445914

Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gemcitabine and nab-paclitaxel
Number of subjects: 90
Study: 38445950

Group type: EXPERIMENTAL
Intervention: High-intensity care strategy of guideline-directed medical therapy up-titration
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1072
Study: 38445964

Group type: EXPERIMENTAL
Intervention: Once-weekly dordaviprone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-weekly dordaviprone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38446022

Group type: EXPERIMENTAL
Intervention: Primary antegrade wiring strategy
Number of subjects: 13563
Study: 38446275

Group type: EXPERIMENTAL
Intervention: Evinacumab (5 or 15 mg/kg intravenously every 4 weeks, or 300 or 450 mg subcutaneously every week or every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evinacumab
Number of subjects: 0
Study: 38446281

Group type: EXPERIMENTAL
Intervention: CsA 0.1% cationic emulsion (CE)
Number of subjects: 20
Study: 38446309

Group type: EXPERIMENTAL
Intervention: 90-g transplant administered once to the colon (LI)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 90-g transplant administered once to the duodenum (SI)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 90-g transplant administered twice to the distal duodenum (repeated SI)
Number of subjects: 186
Study: 38446316

Group type: EXPERIMENTAL
Intervention: Whole-food, plant-based diet (WFPB) for 8 weeks
Number of subjects: 32
Study: 38446336

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)/vilanterol (VI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC)/vilanterol (VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ICS-containing treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-ICS containing treatments
Number of subjects: 0
Study: 38446341

Group type: EXPERIMENTAL
Intervention: Cenobamate (mean dose 262.5 mg/day)
Number of subjects: 42
Study: 38446353

Group type: EXPERIMENTAL
Intervention: Lu-TLX591 monoclonal antibody (177 Lu-DOTA-rosopatamab) dosed from 1.01-2.85 GBq, 14 days apart
Number of subjects: 18
Study: 38446388

Group type: COMPARATOR
Intervention: HEC122505 single ascending dose (5, 20, 50, 100, 200, 300, or 400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEC122505 multiple ascending dose (20, 50, or 100 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HEC122505 food effect (100 mg single dose after a high-fat, high-calorie meal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38446397

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 828

Group type: COMPARATOR
Intervention: Secukinumab 150 mg
Number of subjects: 828

Group type: COMPARATOR
Intervention: Secukinumab 300 mg
Number of subjects: 828
Study: 38446408

Group type: EXPERIMENTAL
Intervention: Proactive medical and social care (Intervention Group)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 255
Study: 38446419

Group type: EXPERIMENTAL
Intervention: IDH1 R132 mutation positive patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (IDH1 R132 mutation negative patients)
Number of subjects: 0
Study: 38446471

Group type: EXPERIMENTAL
Intervention: Active tDCS (2-mA anodal) plus VR
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham tDCS plus VR
Number of subjects: 54
Study: 38446481

Group type: EXPERIMENTAL
Intervention: Rapid syndromic PCR testing (BioFire FilmArray Pneumonia plus Panel) and standard of care
Number of subjects: 374

Group type: COMPARATOR
Intervention: Standard microbiological diagnostics alone
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Rapid syndromic PCR testing
Number of subjects: 374
Study: 38446482

Group type: EXPERIMENTAL
Intervention: Invasive treatment (coronary angiography and revascularization if feasible, n=84)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conservative treatment (medical treatment with coronary angiography only if recurrent ischemia, n=83)
Number of subjects: 167
Study: 38446539

Group type: EXPERIMENTAL
Intervention: ChatGPT-generated outputs
Number of subjects: 11

Group type: COMPARATOR
Intervention: Human-generated outputs
Number of subjects: 11
Study: 38446568

Group type: EXPERIMENTAL
Intervention: Germ line NBN variant carriers (heterozygous genotypes)
Number of subjects: 4325

Group type: COMPARATOR
Intervention: B-ALL patients with germ line NBN variants
Number of subjects: 4325

Group type: EXPERIMENTAL
Intervention: Functional assays for NBN variants
Number of subjects: 4325
Study: 38446574

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT)
Number of subjects: 0
Study: 38446676

Group type: EXPERIMENTAL
Intervention: Detection of microplastics and nanoplastics (MNPs) in carotid artery plaque
Number of subjects: 304

Group type: COMPARATOR
Intervention: No detection of microplastics and nanoplastics (MNPs) in carotid artery plaque
Number of subjects: 304
Study: 38446675

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin and pembrolizumab
Number of subjects: 886

Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine and cisplatin or carboplatin)
Number of subjects: 886
Study: 38446754

Group type: EXPERIMENTAL
Intervention: Preoperative frailty (mFI ≥ 0.21)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Nonfrailty group (mFI < 0.21)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Preoperative frailty (mFI)
Number of subjects: 536
Study: 38446792

Group type: EXPERIMENTAL
Intervention: Daraja intervention (n=250)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Enhanced standard care (n=250)
Number of subjects: 500
Study: 38446828

Group type: EXPERIMENTAL
Intervention: Misdiagnosed patients with COPD
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Investigated patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Qualitative analysis from healthcare professionals and misdiagnosed patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Support from respiratory specialists
Number of subjects: 206
Study: 38446867

Group type: EXPERIMENTAL
Intervention: Dissolved oxygen during VV ECMO support
Number of subjects: 0
Study: 38446860

Group type: EXPERIMENTAL
Intervention: In Vivo treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 83
Study: 38446982

Group type: EXPERIMENTAL
Intervention: Encorafenib and binimetinib
Number of subjects: 5
Study: 38447065

Group type: EXPERIMENTAL
Intervention: High-Intensity Exercise
Number of subjects: 30
Study: 38447094

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 1
Study: 38447095

Group type: EXPERIMENTAL
Intervention: 5% nicotine e-cigarettes (EC) for 8 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 4 mg oral nicotine pouches (ONP) for 8 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Assessment-only control (CC)
Number of subjects: 45
Study: 38447107

Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration and lumbar puncture under sedation or general anesthesia
Number of subjects: 893
Study: 38447116

Group type: EXPERIMENTAL
Intervention: Pathogen-reduced platelet components (PRPCs)
Number of subjects: 2291

Group type: COMPARATOR
Intervention: Conventional platelet components (CPCs)
Number of subjects: 2291
Study: 38447497

Group type: EXPERIMENTAL
Intervention: Aquatic Therapy (AT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Land-Based Therapy (LBT)
Number of subjects: 40
Study: 38447622

Group type: EXPERIMENTAL
Intervention: Music Listening (ML)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study: 38447697

Group type: EXPERIMENTAL
Intervention: Pegloticase (8mg every 2 weeks) + Methotrexate (15mg/week orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Pegloticase (8mg every 2 weeks) + Placebo (PBO)
Number of subjects: 8
Study: 38447814

Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 38448059

Group type: EXPERIMENTAL
Intervention: Systematic VA-ECMO initiation before the first pulmonary artery cross-clamp
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-demand VA-ECMO initiation based on haemodynamic and respiratory needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic VA-ECMO initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-demand VA-ECMO initiation
Number of subjects: 0
Study: 38448064

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment with telemonitoring, home visits by a CPAP technician or nurse at CPAP initiation, followed up for 6 months.
Number of subjects: 250
Study: 38448065

Group type: EXPERIMENTAL
Intervention: Individualised physical exercise training
Number of subjects: 115
Study: 38448070

Group type: EXPERIMENTAL
Intervention: Universal screening using capillary blood sampling
Number of subjects: 1500
Study: 38448081

Group type: EXPERIMENTAL
Intervention: Thoracoscopic LAA clipping
Number of subjects: 290

Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 290
Study: 38448281

Group type: EXPERIMENTAL
Intervention: elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Baseline relative abundances of potential pathogens
Number of subjects: 34
Study: 38448403

Group type: EXPERIMENTAL
Intervention: Pegaspargase 2500 IU/m
Number of subjects: 22
Study: 38448625

Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Double-pigtail plastic stents (DPS)
Number of subjects: 64
Study: 38448797

Group type: EXPERIMENTAL
Intervention: 28 mm cryoballoon
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 28/31 mm variable size cryoballoon
Number of subjects: 325
Study: 38448804

Group type: EXPERIMENTAL
Intervention: Prehabilitation (frailty screening, shared decision-making, physiotherapy, nutrition counselling, etc.) for 3 weeks prior to surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard preoperative care (Control)
Number of subjects: 0
Study: 38448874

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Internet-delivered intervention
Number of subjects: 42
Study: 38448895

Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (GCBT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 33
Study: 38448918

Group type: EXPERIMENTAL
Intervention: UNIMMAP-MMS
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study: 38448965

Group type: EXPERIMENTAL
Intervention: Corneal crosslinking (CXL) treatment before transplantation, with possible repeat if insufficient reduction of corneal neovascularization is observed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corneal crosslinking (CXL) treatment with additional fine needle diathermy on the day of transplantation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No pretreatment (control group).
Number of subjects: 0
Study: 38449031

Group type: EXPERIMENTAL
Intervention: Caregiver Interaction Profile training
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 200
Study: 38449345

Group type: EXPERIMENTAL
Intervention: Cumulative health status measured by Kansas City Cardiomyopathy Questionnaire (KCCQ)-12
Number of subjects: 2328
Study: 38449377

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 400 mg IV infusion on day 1 of a 42-day cycle plus SBRT delivered in 1-5 fractions starting on C1D15-28.
Number of subjects: 0

Group type: COMPARATOR
Intervention: SBRT in addition to current therapy for patients who have started an immune checkpoint inhibitor within 60 days.
Number of subjects: 0
Study: 38449767

Group type: EXPERIMENTAL
Intervention: Pre-transplant phase
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4-weeks post-transplant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6-months post-transplant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Therapeutic adherence
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blood levels of prescribed drugs
Number of subjects: 60
Study: 38449916

Group type: COMPARATOR
Intervention: Anti-PD-1 monoclonal antibody infusions
Number of subjects: 5
Study: 38449910

Group type: EXPERIMENTAL
Intervention: 12-session housing skills training intervention
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Training and technical assistance for providers
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Group-based format of the intervention
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Adaptations to the intervention (e.g., drop-in, open group format)
Number of subjects: 6
Study: 38450075

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a-tDCS) combined with 4-week visuomotor stepping training (VST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4-week visuomotor stepping training (VST)
Number of subjects: 10
Study: 38450099

Group type: EXPERIMENTAL
Intervention: LADSS Group 1 (positive slope)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LADSS Group 2 (flat slope)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LADSS Group 3 (negative slope)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LADSS
Number of subjects: 66
Study: 38450148

Group type: EXPERIMENTAL
Intervention: Youth sport (YS) participation
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) outcomes
Number of subjects: 97
Study: 38450236

Group type: EXPERIMENTAL
Intervention: 30 mg/day elemental Zn
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 mg/day elemental Zn
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38450375

Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel (IV infusion, paclitaxel dose: 175 mg/m2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LDE-paclitaxel
Number of subjects: 40
Study: 38450496

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with SAPIEN 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 38450513

Group type: EXPERIMENTAL
Intervention: Mitapivat therapy
Number of subjects: 15
Study: 38450551

Group type: EXPERIMENTAL
Intervention: Aripiprazole 30 mg tablet orally 3 hours before surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo tablet 3 hours before surgery
Number of subjects: 80
Study: 38451170

Group type: EXPERIMENTAL
Intervention: Brief video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38451273

Group type: EXPERIMENTAL
Intervention: Tiragolumab 600 mg plus Atezolizumab 1200 mg intravenous every 3 weeks
Number of subjects: 20
Study: 38451303

Group type: EXPERIMENTAL
Intervention: Surgical management involving revision arthroplasty by experienced surgeons
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Open surgical approach
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Overall management of PPF
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Management involving surgical delay of over 100 hours and lack of geriatric co-management
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Co-management
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Prosthesis revision
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Discharge instructions
Number of subjects: 1387

Group type: EXPERIMENTAL
Intervention: Predictors of in-hospital outcomes
Number of subjects: 1387
Study: 38451426

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 1192
Study: 38451491

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) to a dose of 50 Gy in 5 fractions every other day.
Number of subjects: 39
Study: 38451509

Group type: EXPERIMENTAL
Intervention: Water-free cyclosporine ophthalmic solution, 0.1% (1 eye drop in each eye twice daily)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Vehicle (1 eye drop in each eye twice daily)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Water-free cyclosporine ophthalmic solution, 0.1%
Number of subjects: 206

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 206
Study: 38451525

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3 months of DAPT
Number of subjects: 1387

Group type: COMPARATOR
Intervention: DAPT for 12 months
Number of subjects: 1387
Study: 38451604

Group type: EXPERIMENTAL
Intervention: Lacosamide (initial dose 50 mg orally twice a day, increasing to a maximum of 400 mg/day for 7 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lacosamide + Opioid therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Opioid therapy
Number of subjects: 6
Study: 38451782

Group type: EXPERIMENTAL
Intervention: Preoperative global mean diffusivity (MD)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Preoperative global mean kurtosis (MK)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Preoperative global fractional anisotropy (FA)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Postoperative mean diffusivity (MD) after 3 months
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Postoperative mean diffusivity (MD) after 12 months
Number of subjects: 325
Study: 38452035

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg orally twice daily
Number of subjects: 7
Study: 38452059

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg daily with Sildenafil 100 mg daily
Number of subjects: 29
Study: 38452111

Group type: EXPERIMENTAL
Intervention: Integrated PrEP and ART delivery
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: PrEP initiation by HIV-negative partners
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 83
Study: 38452133

Group type: EXPERIMENTAL
Intervention: PUSH (16 weeks of strength, endurance, balance, and function exercises)
Number of subjects: 37

Group type: COMPARATOR
Intervention: PULSE (seated active range-of-motion exercises and transcutaneous electrical neurostimulation)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: PUSH
Number of subjects: 37

Group type: COMPARATOR
Intervention: PULSE
Number of subjects: 37
Study: 38452136

Group type: EXPERIMENTAL
Intervention: internet-based self-efficacy intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 158
Study: 38452197

Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis (once-monthly 80 mg for 7 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: BPA/CFC prophylaxis (for 6 months prior to switching)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 80

Group type: COMPARATOR
Intervention: BPA/CFC prophylaxis
Number of subjects: 80
Study: 38452207

Group type: EXPERIMENTAL
Intervention: Nilotinib with cytarabine (Ara-C) during consolidation (arm A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Nilotinib without cytarabine (Ara-C) during consolidation (arm B)
Number of subjects: 156
Study: 38452238

Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only strategy
Number of subjects: 1445
Study: 38452283

Group type: EXPERIMENTAL
Intervention: β3-AR agonist mirabegron (300 mg/day) for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 70